Pyxis Oncology is trading 6% down at $2.97 in pre-market, pulling back after sharp gains over the last two sessions.
- The stock recently jumped on a $50 million private placement with attached warrants and supportive analyst commentary, which extended its funding runway and sparked a short-term rally.
- Today’s move appears to be profit-taking and consolidation rather than a reaction to fresh company-specific news.